obesity treatment

CMS launches Medicare GLP-1 Bridge program July 2026, offering Novo Nordisk's Wegovy at $50 monthly copay. Amazon Pharmacy expands oral Ozempic access.

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.

Novo Nordisk reported Q1 2026 adjusted operating profit of DKK 32.9B, raising 2026 guidance on Wegovy® pill's success with 2M total prescriptions since January launch.

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.

Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.

Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.

Clinical-stage biotech Kailera prices IPO at $16/share, raising $625M. Company debuts on Nasdaq ($KLRA) April 17 with positive Phase 2 obesity drug data.

GoodRx shares rose 2.69% as the platform expands access to Novo Nordisk's Wegovy HD at $399/month, capitalizing on the surging self-pay GLP-1 obesity treatment market.

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.

Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.

Novo Nordisk launches Wegovy subscription program with monthly pricing from $249-$329, offering up to $1,200 annual savings via telehealth partners.

Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.